The procurement contact named on the official notice.

The Authority is seeking to identify existing and potential suppliers of lumpy skin disease vaccine who have products with robust evidence of quality, safety, and efficacy.

We are keen to hear from suppliers who are in a position to supply suitable lumpy skin disease vaccine products to the UK vaccine bank as early as March 2025. <br/><br/>The Authority is specifically interested in: <br/>- Vaccines against lumpy skin disease. <br/>- The efficacy and period (onset and duration) of immunity in the target species.<br/>- Safety data in the target species.<br/>- The proposed number of doses in the vaccination schedule. <br/>- Storage conditions. <br/>- Any information that might be provided about potential cost.<br/>- Whether the vaccine is or will be manufactured under the conditions of Good Manufacturing Practice (GMP). <br/>- Whether quality aspects are considered such that the vaccine is manufactured and stored according to the WOAH Terrestrial Manual Chapter 3.4.12.<br/><br/>Please note that the Authority will not be considering heterologous vaccine products. <br/> <br/>The Authority is seeking this information to inform decisions around guarantees of supply to the UK market.

An estimated total value is therefore not provided at this stage.